Table 3 Comparison of LVEF, hs-TnI and QTc at each time point between non-cardiotoxicity group and cardiotoxicity group.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Parameter | No cardiotoxicity n = 353 | Cardiotoxicity n = 67 | P value |
---|---|---|---|
LVEF (%) | |||
Baseline | 65.07 ± 2.59 | 65.36 ± 1.94 | 0.404 |
3m | 64.67 ± 2.99 | 63.45 ± 2.57 | 0.003* |
6m | 63.87 ± 3.99 | 61.93 ± 3.16 | 0.001* |
9m | 62.17 ± 4.11 | 59.65 ± 4.84 | < 0.001* |
12m | 61.39 ± 4.01 | 56.44 ± 4.30 | < 0.001* |
hsTnI (pg/ml) | |||
Baseline | 2.32 ± 3.03 | 2.61 ± 2.21 | 0.063 |
3m | 2.33 ± 2.66 | 3.34 ± 2.69 | 0.012* |
6m | 2.41 ± 2.93 | 3.99 ± 3.16 | 0.001* |
9m | 2.78 ± 3.43 | 4.60 ± 3.40 | < 0.001* |
12m | 2.85 ± 3.87 | 4.87 ± 3.61 | < 0.001* |
QTc (ms) | |||
Baseline | 405.19 ± 22.27 | 415.86 ± 34.90 | 0.002* |
3m | 410.26 ± 28.94 | 430.63 ± 36.73 | < 0.001* |
6m | 417.58 ± 37.43 | 444.42 ± 45.19 | < 0.001* |
9m | 412.96 ± 29.89 | 440.26 ± 38.15 | < 0.001* |
12m | 414.12 ± 26.97 | 438.85 ± 42.92 | < 0.001* |